ReviewPathogens (Basel, Switzerland)2021
Microbiota and Drug Response in Inflammatory Bowel Disease.
Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 36 citations in OpenAlex.
- Short-Chain Fatty Acids: Microbial Metabolites Driving Gut-Eye Axis Signaling.Comprehensive physiology · 2026Review
- Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease.Frontiers in cellular and infection microbiology · 2026Article
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- Probiotic drug interactions in ulcerative colitis: a microbiota and metabolite perspective.Frontiers in microbiology · 2026Review
- Bidirectional Interplay Between IBD Therapies and the Gut Microbiota: A Pharmacomicrobiomic Approach to Personalized Treatment.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Review
- Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects ofMicroorganisms · 2025Article
- Microbial Patterns in Newly Diagnosed Inflammatory Bowel Disease Revealed by Presence and Transcriptional Activity - Relationship to Diagnosis and Outcome.Clinical and experimental gastroenterology · 2025Article
- The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis.Frontiers in cellular and infection microbiology · 2025Article
- Fecal microbiota and metabolites in the pathogenesis and precision medicine for inflammatory bowel disease.Precision clinical medicine · 2024Review
- The gut microbiome: an important factor influencing therapy for pediatric acute lymphoblastic leukemia.Annals of hematology · 2024Review
- Milk andAmerican journal of physiology. Gastrointestinal and liver physiology · 2024Article
- Predictive biomarkers for anti-TNF alpha therapy in IBD patients.Journal of translational medicine · 2024Review
- Precision medicine in inflammatory bowel disease.Precision clinical medicine · 2023Review
- Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches.Microbiome research reports · 2023Article
- Unraveling the Impact of Gut and Oral Microbiome on Gut Health in Inflammatory Bowel Diseases.Nutrients · 2023Review
- Nasotracheal Microbiota of Nestlings of Parent White storks with Different Foraging Habits in Spain.EcoHealth · 2023Article
- Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors.International journal of molecular sciences · 2023Article
- Association between vitamin D level and pediatric inflammatory bowel disease: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Review
- The gastrointestinal antibiotic resistome in pediatric leukemia and lymphoma patients.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
A mutualistic relationship between the composition, function and activity of the gut microbiota (GM) and the host exists, and the alteration of GM, sometimes referred as dysbiosis, is involved in various immune-mediated diseases, including inflammatory bowel disease (IBD). Accumulating evidence suggests that the GM is able to influence the efficacy of the pharmacological therapy of IBD and to predict whether individuals will respond to treatment. Additionally, the drugs used to treat IBD can modualate the microbial composition. The review aims to investigate the impact of the GM on the pharmacological therapy of IBD and vice versa. The GM resulted in an increase or decrease in therapeutic responses to treatment, but also to biotransform drugs to toxic metabolites. In particular, the baseline GM composition can help to predict if patients will respond to the IBD treatment with biologic drugs. On the other hand, drugs can affect the GM by incrementing or reducing its diversity and richness. Therefore, the relationship between the GM and drugs used in the treatment of IBD can be either beneficial or disadvantageous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.